Literature DB >> 15322526

Strategies for disease modification in Alzheimer's disease.

Martin Citron1.   

Abstract

Treating Alzheimer's disease (AD) is the biggest unmet medical need in neurology. Current drugs improve symptoms, but do not have profound disease-modifying effects. Three main classes of disease-modification approaches can be defined: one that is broadly neurotrophic or neuroprotective, one that targets specific aspects of AD pathology, and one that is based on epidemiological observation. This review discusses all three approaches, with particular emphasis on anti-amyloid strategies - currently the most active area of investigation. The approaches that are reviewed include secretase inhibition, amyloid-beta aggregation inhibition, immunotherapy and strategies that might indirectly affect the amyloid pathway.

Entities:  

Mesh:

Year:  2004        PMID: 15322526     DOI: 10.1038/nrn1495

Source DB:  PubMed          Journal:  Nat Rev Neurosci        ISSN: 1471-003X            Impact factor:   34.870


  97 in total

1.  Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver.

Authors:  Neha Sehgal; Alok Gupta; Rupanagudi Khader Valli; Shanker Datt Joshi; Jessica T Mills; Edith Hamel; Pankaj Khanna; Subhash Chand Jain; Suman S Thakur; Vijayalakshmi Ravindranath
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

Review 2.  Disease-modifying therapies in Alzheimer's disease: how far have we come?

Authors:  Michael Hüll; Mathias Berger; Michael Heneka
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 3.  The development of anti-amyloid therapy for Alzheimer's disease : from secretase modulators to polymerisation inhibitors.

Authors:  Paul S Aisen
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 4.  Small molecule inhibitors of amyloid β peptide aggregation as a potential therapeutic strategy for Alzheimer's disease.

Authors:  Qin Nie; Xiao-guang Du; Mei-yu Geng
Journal:  Acta Pharmacol Sin       Date:  2011-04-18       Impact factor: 6.150

Review 5.  Lipoprotein receptors and cholesterol in APP trafficking and proteolytic processing, implications for Alzheimer's disease.

Authors:  Maria-Paz Marzolo; Guojun Bu
Journal:  Semin Cell Dev Biol       Date:  2008-10-17       Impact factor: 7.727

Review 6.  Hacking the code of amyloid formation: the amyloid stretch hypothesis.

Authors:  M Teresa Pastor; Alexandra Esteras-Chopo; Luis Serrano
Journal:  Prion       Date:  2007-01-05       Impact factor: 3.931

Review 7.  Alzheimer's disease: which type of amyloid-preventing drug agents to employ?

Authors:  Hyunbum Jang; Laura Connelly; Fernando Teran Arce; Srinivasan Ramachandran; Ratnesh Lal; Bruce L Kagan; Ruth Nussinov
Journal:  Phys Chem Chem Phys       Date:  2013-02-28       Impact factor: 3.676

Review 8.  New methods to explore marine resources for Alzheimer's therapeutics.

Authors:  P Williams; A Sorribas; Z Liang
Journal:  Curr Alzheimer Res       Date:  2010-05       Impact factor: 3.498

9.  Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice.

Authors:  A V Savonenko; T Melnikova; F M Laird; K-A Stewart; D L Price; P C Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-02       Impact factor: 11.205

Review 10.  Transgenic Drosophila models of Alzheimer's disease and tauopathies.

Authors:  Kanae Iijima-Ando; Koichi Iijima
Journal:  Brain Struct Funct       Date:  2009-12-05       Impact factor: 3.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.